Drug profile · INN
fremanezumab
AJOVY
fremanezumab (AJOVY) is a calcitonin gene-related peptide antagonist. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Nervous system (N02) N02CD03
Patents linked 0
Pipeline programs 10
News articles 0
Congress events 1
Drug details — fremanezumab
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
fremanezumab (AJOVY) is a calcitonin gene-related peptide antagonist. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN fremanezumab
Brand AJOVY
Mechanism Calcitonin gene-related peptide antagonist
Target Calcitonin gene-related peptide
Therapeutic class Nervous system (N02)
ATC code N02CD03
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Calcitonin gene-related peptide antagonist
Primary target: Calcitonin gene-related peptide
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Congress & event coverage
- PresentationIMPHARMA2026
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fremanezumab?
fremanezumab (AJOVY) is a calcitonin gene-related peptide antagonist. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for fremanezumab?
AJOVY is a marketed brand name for fremanezumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.